Severe CRS management in CAR-T cell therapy

DOI

Bibliographic Information

Other Title
  • CAR-T細胞療法における重症CRSマネージメントの経験

Description

<p>The prognosis of relapsed/refractory acute lymphoblastic leukemia remains poor. Recently developed CAR-T cell therapy is one of the promising new therapies because it provides a high response rate in patients with this leukemia. However, unique side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can happen and become potentially very severe. Massive cytokine production by activated CAR-T cells is postulated to be the cause, but this needs more research to better cope with it. On the basis of our experience in the ELIANA trial, we discuss the flow of CAR-T therapy, the main clinical course, and the management of CRS.</p>

Journal

Keywords

Details 詳細情報について

  • CRID
    1390853022611274112
  • NII Article ID
    130008116126
  • DOI
    10.11412/jspho.58.194
  • ISSN
    21895384
    2187011X
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top